Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Bio-Rad's Chief Operating Officer Andrew Last to Retire


Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a search for his successor.

Dr. Last joined Bio-Rad in April of 2019 with over 30 years of experience in global operations management spanning the life sciences.

"Andy's extensive operations experience, technical acumen, and leadership abilities have been invaluable to Bio-Rad over the past five years," said Norman Schwartz, Bio-Rad President and CEO. "We have made significant progress on our transformational objectives, including cost structure, core processes, and supply chain improvements, while effectively navigating various macroeconomic challenges."

Dr. Last stated, "When I reflect on my tenure at Bio-Rad, I am most proud of the team we have built and the operations and management systems we have put in place. I am confident that these accomplishments have positioned Bio-Rad well for the next phase of its continued journey of transformation and growth."

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.


These press releases may also interest you

at 16:20
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The...

at 16:19
The Autorité des marchés financiers ("AMF") cautions Québec consumers about the website dr-hypotheque.ca.  According to information...

at 16:15
Block, Inc. will release financial results for the second quarter of 2024 on Thursday, August 1, 2024, after market close. Block will also host a conference call and earnings webcast at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time on the same day...

at 16:15
Snap Inc. will hold its quarterly conference call to discuss second quarter 2024 financial results on Thursday, August 1, 2024 at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). A live webcast and replay of the conference call will be accessible...

at 16:10
bluebird bio, Inc. today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James...

at 16:10
AppLovin Corporation, ("AppLovin" or the "Company") the leading marketing platform, today announced it will report financial results for the second quarter on Wednesday, August 7, 2024 after the U.S. stock market closes. An accompanying webinar...



News published on and distributed by: